This Article Full Text Full Text (PDF) All Versions of this Article: 38/5/1652    most recent STROKEAHA.107.485250v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gorelick, P. B. Search for Related Content PubMed PubMed Citation Articles by Gorelick, P. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID WARFARIN Medline Plus Health Information Atrial Fibrillation Blood Thinners Stroke Related Collections Anticoagulants

(Stroke. 2007;38:1652.)
© 2007 American Heart Association, Inc.

Emerging Therapies

Combining Aspirin With Oral Anticoagulant Therapy

Is This a Safe and Effective Practice in Patients With Atrial Fibrillation?

From the Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, Ill.

Correspondence to Philip B. Gorelick, MD, MPH, Department of Neurology and Rehabilitation, University of Illinois College of Medicine at Chicago, 912 South Wood St, Rm 855N, Chicago, Illinois 60612. E-mail pgorelic@uic.edu

Marc Fisher MD Kennedy Lees MD Section Editors

Key Words: aspirin • bleeding complications • warfarin • ximelagatran

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
In persons with cerebral ischemia caused by atrial fibrillation (AF) and high risk of stroke based on an overall score of a validated risk stratification scheme such as CHADS2^*, adjusted-dose warfarin is recommended for those who have no clinically significant contraindication.^1,2 When there is AF, adjusted-dose warfarin is estimated to reduce the risk of stroke by about 60% or more and by about 45% more than aspirin.¹ The combination of adjusted-dose warfarin plus aspirin administered to AF patients may offer theoretical advantages such as enhanced stroke prevention efficacy in high-risk persons or improved protection against myocardial ischemic events in those who have coronary artery disease or diabetes.³ The recently published American Heart Association/American Stroke Association recurrent stroke prevention guideline suggests, however, no data indicate that either increasing the intensity of oral anticoagulation or add-on antiplatelet therapy provides further ischemic protection in AF patients.² In a post hoc analysis, the Stroke Prevention Using an ORal Thrombin Inhibitor in atrial Fibrillation (SPORTIF) investigators studied the risks and benefits of combining aspirin with oral anticoagulant therapy in patients with AF.³

	SPORTIF Trial Design

 
SPORTIF III and V trials were designed to determine whether the direct oral thrombin inhibitor ximelagatran (36 mg twice daily) was noninferior to vitamin K antagonist therapy with adjusted-dose warfarin (international normalized ratio 2.0 to 3.0) for prevention of stroke and systemic embolism in high-risk patients with nonvalvular AF.³ The SPORTIF studies were multicenter, randomized trials. SPORTIF III was open-label and carried out in Europe, Asia, and Australasia, and SPORTIF V was . . . [Full Text of this Article]

This article has been cited by other articles:

				P. B. Gorelick Cerebral Microbleeds: Evidence of Heightened Risk Associated With Aspirin Use Arch Neurol, June 1, 2009; 66(6): 691 - 693. [Full Text] [PDF]

				A. J. Furlan Does the Combination of Warfarin and Aspirin Have a Place in Secondary Stroke Prevention?: Yes Stroke, May 1, 2009; 40(5): 1942 - 1943. [Full Text] [PDF]

				K. Toyoda, M. Yasaka, K. Iwade, K. Nagata, Y. Koretsune, T. Sakamoto, S. Uchiyama, J. Gotoh, T. Nagao, M. Yamamoto, et al. Dual Antithrombotic Therapy Increases Severe Bleeding Events in Patients With Stroke and Cardiovascular Disease: A Prospective, Multicenter, Observational Study Stroke, June 1, 2008; 39(6): 1740 - 1745. [Abstract] [Full Text] [PDF]

				A. Ono, I. Kawamura, and T. Fujita Letter Regarding Article by Hylek et al, "Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation" Circulation, November 13, 2007; 116(20): e538 - e538. [Full Text] [PDF]

				T. Watson and G. Y.H. Lip Combining Antiplatelet Drugs and Oral Anticoagulant Therapy in Atrial Fibrillation: Acute Coronary Syndromes and/or Percutaneous Coronary Intervention/Stenting Revisited Stroke, October 1, 2007; 38(10): e107 - e108. [Full Text] [PDF]